Novo Nordisk shares riding high on success of Wegovy
This bullish stock performance follows on the heels of a key study that found Wegovy, the Novo Nordisk weight loss drug, reduces cardiac risks and related mortalities in obese people. Those involved in the study took the highest dose of the drug and consequently experienced a drop in blood sugar and inflammation, two of the…
Read more